Kiniksa Pharmaceuticals International Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6
Kiniksa Pharmaceuticals International has a total shareholder equity of $437.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $555.3M and $118.3M respectively.
Anahtar bilgiler
0%
Borç/özkaynak oranı
US$0
Borç
| Faiz karşılama oranı | n/a |
| Nakit | US$223.78m |
| Eşitlik | US$437.01m |
| Toplam yükümlülükler | US$118.29m |
| Toplam varlıklar | US$555.30m |
Son finansal sağlık güncellemeleri
We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn
Feb 28
We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow
Nov 10We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Mar 18Recent updates
Kiniksa Pharmaceuticals: Looking In On A Developing Growth Story
Oct 07Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Aug 07Kiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 Beat
Jul 24Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Share Price Is Matching Sentiment Around Its Revenues
Jun 19Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Apr 25Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape
Apr 24Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates
Mar 01We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn
Feb 28The Market Doesn't Like What It Sees From Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Revenues Yet
Dec 18We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow
Nov 10Investors Don't See Light At End Of Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Tunnel
Apr 18Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings
Nov 10Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%
Aug 04Kiniksa Pharmaceuticals GAAP EPS of -$0.29 beats by $0.15, revenue of $26.97M misses by $1.58M, reaffirms FY revenue guidance
Aug 03Analysts Are Updating Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Estimates After Its First-Quarter Results
May 05We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Mar 18Kiniksa: Latest Earnings Beat Shows Light At The End Of The Tunnel
Nov 25Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?
Nov 04Kiniksa: Unexciting, Slow Growth Stock
Aug 13We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Jul 31Kiniksa outlines development path for mavrilimumab after FDA feedback
Jun 08Kiniksa: A Look At Mavrilimumab
May 03Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation
Apr 17Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: KNSA's short term assets ($311.3M) exceed its short term liabilities ($96.0M).
Uzun Vadeli Yükümlülükler: KNSA's short term assets ($311.3M) exceed its long term liabilities ($22.3M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: KNSA is debt free.
Borcun Azaltılması: KNSA has not had any debt for past 5 years.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: Whilst unprofitable KNSA has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Tahmini Nakit Akışı: KNSA is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 34.8% per year.